Androgen Signaling and Gonadotropic Support in Male Reproduction
The foundational mechanisms governing male fertility rely heavily on hypothalamic-pituitary-gonadal axis integrity. Androgen receptor signaling via testicular Sertoli and peritubular myoid cells is strictly required for spermatogenesis, regulating events from spermatogonial maintenance through meiosis completion to spermiation.
In clinical settings characterized by congenital hypogonadotropic hypogonadism or syndromic presentations like Oliver-McFarlane syndrome, combined gonadotropin therapy utilizing recombinant FSH and hCG successfully induces pubertal development and restores partial testicular volume. These interventions can successfully enable sperm retrieval via micro-TESE, though historical factors such as cryptorchidism act as strong negative predictors of success.
Combating Oxidative Stress and Diminished Ovarian Reserve
Cellular aging in the female germline is heavily driven by reactive oxygen species that accelerate oocyte deterioration and germ cell apoptosis. While antioxidant interventions theoretically mitigate oxidative stress, clinical translation into improved live birth rates remains challenging.
To address diminished ovarian reserve, clinicians frequently employ personalized protocols incorporating adjuncts such as DHEA, growth hormone, and intraovarian platelet-rich plasma (PRP). Although non-controlled series and animal models suggest biochemical improvements and restored ovulation markers, these interventions are largely categorized as targeted or trial-only due to conflicting trial outcomes and a shortage of large-scale, blinded randomized controlled trials.